z-logo
Premium
Effect of supplementation with astaxanthin in CD1 mice submitted to chronic stress in Peyer's patches (638.6)
Author(s) -
MartinezCarrillo Beatriz,
Oros Rigoberto,
Delgadillo Angeles,
ValdésRamos Roxana
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.638.6
Subject(s) - astaxanthin , immune system , cd8 , oxidative stress , cd3 , flow cytometry , medicine , chemistry , endocrinology , immunology , biochemistry , carotenoid
Astaxanthin is a powerful antioxidant, it decreases oxidative stress, inflammatory response and increases the immune response. Chronic stress stimulates the secretion of hormones that affect the immune system, such an effect has not been studied at the level of the intestinal mucosa. The objective is to determine the effect of supplementation with astaxanthin in CD1 mice submitted to chronic stress in Peyer's patches of the intestinal mucosae. 32 CD1 10‐week old mice were used, 30‐35 g/weight, divided into 4 groups: Control (CL), chronic stress (CS), astaxanthin (A) Chronic stress plus astaxanthin (EC + A); astaxanthin was administered orally at doses of 4 mg/g. An unpredictable chronic stress scheme was used. T‐lymphocytes (CD3+, CD4+ and CD8+) and B (CD19+) were determined by flow cytometry. CD3+ T‐lymphocytes increased as follows: EC (40.57 ± 9.88), EC + A (30.49 ± 6.46), A (38.98 ± 9.06) compared with CL (27.47 ± 7.77), with F = 4.88 (p 蠄 0.004); at the expense of TCD4+ cells: CL (23.14 ± 5.85), EC (30.86 ± 6.28), EC + a (33.82 ± 7.41), A (28.92 ± 5.61), F = 9.04 (p 蠄 0.001) and TCD8+, CL (3.51 ± 1.24), EC (5.83 ± 1.65), EC + A (6.68 ± 1.35), A (8.26 ± 1.67) F = 10.24 (p 蠄 0.001). B cells showed no significant differences. Astaxanthin enhances the immune response in Peyer's patches, altering the normal proportion TCD4+ / CD8+. Grant Funding Source : Universidad Autónoma del Estado de México, Promep

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here